|
|
|
| Avelox® (Moxifloxacin) excels in comparison with highly potent combination regimen in the treatment of hospitalised patients with community-acquired pneumonia | | |
| Prospective, randomised, double-blind study shows Avelox® monotherapy to be a highly effective, safe and convenient treatment option in vulnerable patient populations | | |
See More
>>
| | |
| New study data confirm excellent speed of eradication by Avelox® (moxifloxacin HCl) | | |
| Complete eradication of pathogens in acute bacterial sinusitis after only three days of treatment | | |
See More
>>
| | |
| GIANT Study: Many more women affected by acute exacerbations of chronic bronchitis (AECBs) than widely believed | | |
| Largest ever antibiotic study sheds new light on AECBs and confirms effective antibiotic therapy with Avelox® can reduce the significant negative impact on patients’ quality of life | | |
See More
>>
| | |
| Avelox Approved in US to Treat Complicated Intra-abdominal Infections | | |
| Once-a-day Dosage Offers Effective and Convenient Treatment Option | | |
See More
>>
| | |
| Why shouldn’t patients receive best available antibiotics first? | | |
| Specialists discuss scientific rationale for using more potent antibiotic first to improve clinical outcomes in lower respiratory tract infections and minimise bacterial resistance | | |
See More
>>
| | |
| Experts Promote Earlier Use of More Potent Antibiotics for Treatment of LRTI | | |
| Clinical Guidelines for Treatment of LRTI Should Take Account of New Clinical Data | | |
See More
>>
| | |
| Avelox IV Approved in Europe to Treat Complicated Skin and Skin Structure Infections | | |
| Once-a-day Dosage Offers Effective Treatment Option | | |
See More
>>
| | |
| Avelox® (Moxifloxacin HCl) Study Reports Complete Eradication of Bacteria in Acute Bacterial Sinusitis Patients in Three Days | | |
| Patients with acute bacterial sinusitis (ABS) who took Avelox® (moxifloxacin HCl) experienced a complete eradication of bacteria from their sinuses within three days | | |
See More
>>
| | |
| Study showed Avelox (Moxifloxacin HCl) produced better outcomes than Levofloxacin in acute sinusitis | | |
| (IFOS) - Lower costs and lower recurrence rates with moxifloxacin compared with levofloxacin | | |
See More
>>
| | |
| Avelox® (Moxifloxacin HCI) Study Reports Faster Symptom Relief And Earlier Hospital Discharge For Pneumonia Patients | | |
| Antibiotic Also Proves Effective in Treating Multi-Drug Resistant Pneumonia Strains | | |
See More
>>
| | |
| Study Describes New Once-Daily Treatment Regimen For Complicated Intra-Abdominal Infections | | |
| Once-daily Avelox (moxifloxacin HCl/in NaCl injection) Monotherapy was as Effective as Standard 4-Times Daily Therapy in Intra-abdominal Infections | | |
See More
>>
| | |
| New in vitro data shows Avelox (moxifloxacin HCl) is more active against pneumococci, including multi-drug resistant strains, than other antibiotics | | |
| The data analyzed the in vitro activity of antibiotics against S. pneumoniae strains taken from patients in seven countries. | | |
See More
>>
| | |
| Study Describes New Once-Daily Treatment Regimen For Complicated Intra-Abdominal Infections | | |
| The data analyzed the in vitro activity of antibiotics against S. pneumoniae strains taken from patients in seven countries. | | |
See More
>>
| | |
| New study showed Avelox IV (moxifloxacin HCI) highly successful in treating pneumonia in elderly patients | | |
| Compared to the antibiotic Levaquin (levofloxacin) | | |
See More
>>
| | |
| Study shows patients treated with Avelox (moxifloxacin HCI) recovered faster from flare-ups of chronic bronchitis than patients treated with commonly prescribed antibiotics | | |
| This was the principal finding of a study presented today at the 100th International Conference of the American Thoracic Society (ATS) | | |
See More
>>
| | |
| FDA approves Avelox (moxifloxacin HCl) for community acquired pneumonia due to multi-drug resistant Streptococcus pneumoniae | | |
| Approval marks first I.V. antibiotic approved to treat resistant strains of most common cause of bacterial pneumonia | | |
See More
>>
| | |
| Recently published study shows superiority of the antibiotic Avelox (moxifloxacin HCI) in treating acute exacerbations of chronic bronchitis | | |
| The MOSAIC Study Shows that Treatment with Avelox Provides Superior Clinical and Bacteriological Success, More Time Between Bronchitis Flare-Ups and Requires Significantly Fewer Follow-Up Antibiotics Compared to Some Standard Treatments | | |
See More
>>
| | |
| New Data Redefining Clinical Success in the Treatment of Acute Exacerbations of Chronic Bronchitis | | |
| Subgroup Analysis of MOSAIC Study Demonstrated that Treatment with Avelox (moxifloxacin HCl) Provided More Time Between Bronchitis Flare-Ups and Fewer Follow-Up Antibiotics Compared to Standard Treatments | | |
See More
>>
| | |
| Bayer and Paratek Pharmaceuticals Sign Collaboration Agreement for the Novel Antibiotic BAY 73-6944/PTK 0796 | | |
| Bayer AG, Bayer Pharmaceuticals Corp., USA, and Paratek Pharmaceuticals, Inc., USA have signed a Collaborative Development and License Agreement for the novel aminomethylcycline antibiotic BAY 73-6944/PTK 0796 | | |
See More
>>
| | |
| Avalox® i.v. approved in Germany: noticeable drop in treatment costs possible | | |
| Shorter hospitalization period thanks to effective treatment | | |
See More
>>
| | |
| ECCMID 2002, Moxifloxacin IV Reduces Healthcare Costs and Provides Optimal Outcome for Patients hospitalized with Community-Acquired Pneumonia | | |
| Experts attending the 12th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) heard how the intravenous form of moxifloxacin was an attractive new option for the treatment of patients hospitalized with community-acquired pneumonia (CAP) | | |
See More
>>
| | |
| Moxifloxacin Will Be Important in Reducing the Enormous Burden of Community-Acquired RTIs | | |
| Experts attending the 5th International Moxifloxacin Symposium, heard how the rapid action and fast symptom relief offered by Aveloxâ (moxifloxacin), Bayer's new respiratory fluoroquinolone, will have an important role in reducing the enormous burden that community-acquired respiratory tract infections continue to place on patients and healthcare resources worldwide. | | |
See More
>>
| | |
| Moxifloxacin I.V. Likely to Become the New Gold Standard | | |
| Experts attending the 5th International Moxifloxacin Symposium agreed that the intravenous form of moxifloxacin was likely to become the new 'gold standard' for the treatment of patients hospitalized with community-acquired pneumonia (CAP), due to it's clinical superiority, shorter duration and hospitalisation, and higher survival rates for patients. | | |
See More
>>
| | |
| Largest Clinical Trial Ever Conducted in Antibiotics to Focus on Impact and Treatment of Chronic Bronchitis | | |
| Study to Address Unmet Treatment Needs in Condition Affecting Millions Worldwide | | |
See More
>>
| | |
